Abstract
This study aimed to investigate the safety and feasibility of intracoronary injection of human umbilical cord mesenchymal stem cell to the very old patients with coronary chronic total occlusion. 15 consecutive patients received mesenchymal stem cells from human umbilical cord in epicardial coronary artery supplying collateral circulation. The patients were randomly allocated to low-dose 3x106, mid-dose 4x106 and high-dose 5x106 groups. 99mTc single photon emission computed tomography images were obtained at 12 and 24 months. During the 24 month study period, no cases of major cardiac adverse events were reported. None of the patients had coronary care unit admissionshospitalizationsfurther coronary revascularizationacute myocardial infarction and death. The patients had a significant reduction of the infarct size and a remarkable rise in left ventricular ejection fraction with respect to secondary outcomes. This study suggested that stem cell transplantation was safe and feasible. The cells can be utilized to improve in the degree of ischemic myocardium, decrease in the infarct size and rise in left ventricular ejection fraction.
Keywords: Chronic myocardial ischemia, elderly, human umbilical cord-derived mesenchymal stem cells, therapy.
Current Pharmaceutical Design
Title:Safety and Efficacy of Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Treatment for Very Old Patients with Coronary Chronic Total Occlusion
Volume: 21 Issue: 11
Author(s): Xia Li, You-dong Hu, Yan Guo, Ying Chen, Dian-xuan Guo, Hua-lan Zhou, Feng-lin Zhang and Qing-na Zhao
Affiliation:
Keywords: Chronic myocardial ischemia, elderly, human umbilical cord-derived mesenchymal stem cells, therapy.
Abstract: This study aimed to investigate the safety and feasibility of intracoronary injection of human umbilical cord mesenchymal stem cell to the very old patients with coronary chronic total occlusion. 15 consecutive patients received mesenchymal stem cells from human umbilical cord in epicardial coronary artery supplying collateral circulation. The patients were randomly allocated to low-dose 3x106, mid-dose 4x106 and high-dose 5x106 groups. 99mTc single photon emission computed tomography images were obtained at 12 and 24 months. During the 24 month study period, no cases of major cardiac adverse events were reported. None of the patients had coronary care unit admissionshospitalizationsfurther coronary revascularizationacute myocardial infarction and death. The patients had a significant reduction of the infarct size and a remarkable rise in left ventricular ejection fraction with respect to secondary outcomes. This study suggested that stem cell transplantation was safe and feasible. The cells can be utilized to improve in the degree of ischemic myocardium, decrease in the infarct size and rise in left ventricular ejection fraction.
Export Options
About this article
Cite this article as:
Li Xia, Hu You-dong, Guo Yan, Chen Ying, Guo Dian-xuan, Zhou Hua-lan, Zhang Feng-lin and Zhao Qing-na, Safety and Efficacy of Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Treatment for Very Old Patients with Coronary Chronic Total Occlusion, Current Pharmaceutical Design 2015; 21 (11) . https://dx.doi.org/10.2174/1381612821666141126100636
DOI https://dx.doi.org/10.2174/1381612821666141126100636 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelin-1 and Human Platelets
Current Vascular Pharmacology Atheromatosis Extent in Coronary Artery Disease is not Correlated with Apolipoprotein-E Polymorphism and its Plasma Levels, but Associated with Cognitive Decline
Current Alzheimer Research Vasoprotective Actions of the Atrial Natriuretic Peptide
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Adenosine A<sub>2A</sub> Receptor Antagonists as Positron Emission Tomography (PET) Tracers
Current Medicinal Chemistry Luteolin Antagonizes Angiotensin II-Dependent Proliferation and Collagen Synthesis of Cultured rat Cardiac Fibroblasts
Current Pharmaceutical Biotechnology Targeting PPAR Isoforms Following CNS Injury
Current Drug Targets Protective Effects of Curcumin against Iron-induced Toxicity
Current Pharmaceutical Biotechnology Tanshinone IIA Protects Hippocampal Neuronal Cells from Reactive Oxygen Species Through Changes in Autophagy and Activation of Phosphatidylinositol 3-Kinase, Protein Kinas B, and Mechanistic Target of Rapamycin Pathways
Current Neurovascular Research The Role of Platelets in Athero-Thrombotic Events
Current Pharmaceutical Design Protective Effect of Heat Shock Proteins in the Nervous System
Current Neurovascular Research Disruption of Circadian Rhythms and Sleep in Critical Illness: Potential Implications for Angiogenesis After Myocardial Infarction. A Review
Current Pharmaceutical Design Pharmacokinetics of Picroside I, II, III, IV in Rat Plasma by UPLCMS/ MS
Current Pharmaceutical Analysis New Antihypertensive Drugs Under Development
Current Medicinal Chemistry Cardiovascular Disease in Juvenile Idiopathic Arthritis
Current Vascular Pharmacology New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy Functionalized magnetic nanoparticles for biomedical applications
Current Pharmaceutical Design Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity
Current Medicinal Chemistry Cardiovascular Complications of HIV Infection and Treatment
Cardiovascular & Hematological Agents in Medicinal Chemistry Long-term Reproductive and Metabolic Consequences of PCOS
Current Diabetes Reviews Dapagliflozin Protects H9c2 Cells Against Injury Induced by Lipopolysaccharide via Suppression of CX3CL1/CX3CR1 Axis and NF-κB Activity
Current Molecular Pharmacology